EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q3 EPS of ($0.33), $0.17 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $15.2 million versus the consensus estimate of $7.86 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.